secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001437749-26-006229
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar appoints Susan Rodriguez as Chief Commercial and Strategy Officer; NDA submission planned H1 2026
--------------------------------------------------------------------------------

- Susan Rodriguez appointed Chief Commercial and Strategy Officer, effective March 2, 2026.
- She will lead commercial strategy ahead of planned NDA submission for ALXN1840 (Wilson disease) in H1 2026.
- Ms. Rodriguez previously was COO of Avadel, acquired by Alkermes for over $2 billion.
- She also served as CCO of Ardelyx, establishing its first commercial organization and launching two therapies.
- Over 30 years of biopharma leadership; holds MS/BS from University of Pennsylvania.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926006229/0001437749-26-006229-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926006229/mnpr20260302_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-006229

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer